 "Lupin dips on reports of USFDA observations on Goa facility")
Lupin has dipped 7% to Rs 1,736 on the BSE in intra-day trade on media reports that the United States Food and Drug Administration (USFDA) cited nine observations in its inspection of the company's Goa facility last week.
At 12:57 PM, the stock was down 6.3% at Rs 1,751 on the BSE. A combined 2.44 million shares changed hands on the counter on the BSE and NSE.
“The USFDA inspected Lupin’s Goa facility last week and cited 9 observations. The observations are on aspects such as inadequacy and adherence to SOPs,” Lupin said on a clarification on news report.
We are in the midst of putting together a response to address the USFDA’s observations, it added.
Read more from our special coverage on "LUPIN"
We are in the midst of putting together a response to address the USFDA’s observations, it added.
At 12:57 PM, the stock was down 6.3% at Rs 1,751 on the BSE. A combined 2.44 million shares changed hands on the counter on the BSE and NSE.
